AstraZeneca shares slide while Gilead Sciences soar amid merger rumours
Shares in Gilead Sciences climbed higher on Monday, while UK-based AstraZeneca saw its stock take a tumble after reports of a possible merger between the two companies emerged.
Gilead Services share price rally was short-lived, however, with the stock trading flat at $77 at the time of publication, while AstraZeneca closed at £82 per share on Monday.
AstraZeneca-Gilead Sciences negotiations fall flat
Last month, the British drug maker AstraZeneca approached the biotechnology company, which is trailing its drug remdesivir as a potential treatment for the Covid-19 virus, only to have its merger proposal shot down.
AstraZeneca’s shares took a tumble in the wake of the deal rumours, with investors left scratching their heads as to why the British drug maker would entertain a deal with such a poor rationale and require a significant amount of capital to complete.
If the merger did go ahead it would combine the two companies efforts in finding a cure for the coronavirus. However, it would likely create a politically sensitive situation whereby each company’s government’s would seek control over any potential vaccine or treatment created by the pair.
‘[Gilead] may be on the verge of having one of the fastest growing products in the industry, if they can successfully establish profitable commercial pricing for remdesivir,’ SVB Leerink analyst Geoffrey Porges told Reuters..
AstraZeneca: JP Morgan reiterates ‘overweight’ rating
Analysts at JP Morgan remain optimistic about AstraZeneca, with the US-based investment bank reiterating its ‘overweight’ rating for the stock and issuing a target price of £84.27 per share, implying a potential upside of 2.7%.
JP Morgan said that there was a ‘low probability’ of a merger between AstraZeneca and Gilead Sciences, with the US government likely resistant to the company being acquired by a foreign drug maker.
However, the investment bank did concede that if the deal were to go ahead it would support AstraZeneca’s earnings.
‘We calculate this would be highly accretive to Astra earnings in the medium-term, with around 50% core EPS accretion in 2021, 40% accretion in 2022, accretion in the 20s in 2023-25,’ JP Morgan said.
‘In addition, to the EPS accretion, depending on the offer structure, the deal could also allow Astra to de-lever, which in turn could provide more room for pipeline in-licensing.’
How much does it cost to buy UK shares with IG?
There are three ways to ‘buy’ UK shares with IG: spread betting, trading CFDs or buying physical shares. The cost will depend on which method you choose. The table below illustrates how the costs to get exposure to £10,000 of Lloyds stock, which is equivalent to 16,000 shares (quoted at 62.5p a share).
Remember, spread bets and CFDs are derivatives, which come with higher risk and reward than investing.
Cost to get exposure to Lloyds stock
|Spread betting||CFD trading||Share dealing|
|Action||Buy £160 per point||Buy 16,000 share CFDs||Buy 16,000 shares|
|Capital required to open||£2000||£2000||£10,000|
Note: Amounts do not include overnight funding charges and taxes. Spread bets are not subject to tax. CFDs are free from stamp duty, but subject to capital gains tax. Share dealing is subject to both stamp duty and capital gains tax.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.